Abstract: The present disclosure is directed to a drug delivery system in which urate oxidase and metal-based nanoparticles for hydrogen peroxide degradation are loaded in a temperature-sensitive nanocarrier, and a pharmaceutical composition for treating hyperuricemia-related disease comprising the drug delivery system. In the drug delivery system of the present disclosure, urate oxidase and metal-based nanoparticles for hydrogen peroxide degradation are positioned close to each other, thereby effectively removing the toxic substance hydrogen peroxide (H2O2) generated during uric acid degradation. The drug delivery system of the present disclosure may be developed as an active ingredient of a drug for preventing or treating hyperuricemia-related disease.

Abstract: Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nano -particles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. The polysaccharide is able to retain cargo (drugs, diagnostics, etc.) without chemical modification of the agent. The nanoparticle maintains its association with the agent through non-covalent interactions but releases its agent in response to changes in the microenvironment, e.g., at the site of cancer cells or cancer tissue.

Abstract: Polymeric bile acid (pBA) nanoparticles and tolerogenic formulation containing polymeric bile acid nanoparticles for oral delivery and induction of antigen-specific tolerance in a subject may include immunosuppressants and/or disease-specific antigen. Oral delivery results in local organ accumulation as well as systemic delivery of the nanoparticles. Early intervention with the nanoparticles induces antigen-specific tolerance and prevents development of autoimmune disorders. Treatment with the nanoparticles results in long-term antigen-specific immune tolerance, even after cessation of treatment, in autoimmune diseases.

Abstract: A tissue thickness compensator may generally comprise a compressible core comprising a plurality of movable particles, and a wrap surrounding the compressible core. The plurality of movable particles may comprise at least one medicament. A tissue thickness compensator may generally comprise a compressible core comprising a plurality of crushable particles, and a wrap surrounding the compressible core. The plurality of crushable particles may comprise at least one medicament. The compressible core may comprise a material selected from a group consisting of a biocompatible material. The wrap may comprise a material selected from a group consisting of a biocompatible material. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.

Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

Abstract: The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.

Abstract: The present disclosure relates to compositions methods of use and methods of manufacturing, hydrous hydrogel compositions useful as topical oral analgesics including cannabinoids and menthol where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.

Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.

Abstract: The present disclosure relates to chewing gum or lozenge with cannabinoids and menthol including a liquid-filled chewing gum or lozenge with a chewing gum base shell or lozenge candy shell enclosing an internal void therein and a liquid filling in the void, the liquid-filled chewing gum or lozenge including cannabinoids and menthol. The menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.

Abstract: A method of increasing PGC-1? gene expression, decreasing PARIS gene expression, or promoting farnesylation of PARIS in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions.

Abstract: The use of a lignin fraction as a human and animal food supplement ingredient, as well as food supplements comprising the same, are disclosed.

Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.

Abstract: There is herein provided pharmaceutical formulations and kits-of-parts comprising a ?2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a ?3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.

Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.

Abstract: A sterilized chlorhexidine product for topical disinfection includes a package and at least one sterilized chlorhexidine article comprising a cloth. The package includes a film defining an interior volume and the sterilized chlorhexidine article disposed within the interior volume. The package further includes a first sealed end portion positioned at a first end of the film and a second sealed end portion positioned at a second end of the film, wherein the first sealed end portion and the second sealed end portion define a hermetically sealed portion about the interior volume.

Abstract: Niclosamide is an effective therapeutic medicament for the treatment of endometriosis. Niclosamide treatment can reduce the size of endometriotic lesions and reduce cell proliferation in the lesions. Niclosamide treatment can result in the inhibition of proteins and genes associated with inflammatory signaling, including those associated with NF?B and STAT3 activation, but without altering the expression of steroid hormone receptors. Niclosamide can be effective in reducing the growth of endometriotic lesions in female mice without impairing their ability to become pregnant and without negative effect on gestation and offspring. The invention herein is useful in treating symptoms associated with endometriosis, such as reducing the growth of lesions of the endometrium, without disrupting normal reproductive function in females. The invention also relates to derivatives of niclosamide having improved solubility and enhanced efficacy.

Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.

Abstract: An object of the present invention is to provide: a composition for improving intestinal barrier function capable of improving intestinal barrier function; and an agent for enhancing the intestinal barrier function improvement action of gallic acid. The present invention relates to a composition for improving intestinal barrier function, containing: gallic acid as an active ingredient.

Abstract: A germicidal composition comprising at least one fast-acting germicidal agent and at least one slow-acting germicidal agent is provided. The use of a dual germicide system permits the composition to provide an immediate antimicrobial effect when applied to an animal's skin, particularly, a bovine teat, and a residual antimicrobial effect for several hours after application. A method for testing this residual antimicrobial effect is also provided.

Abstract: Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.

Abstract: The present disclosure relates to a composition for preventing, alleviating or treating pruritus and/or atopy using an N-acetylamino acid or an N-acylamino acid having almost no side effects on the human body. Also, the present disclosure relates to a cosmetic composition for moisturizing skin or soothing skin. The composition of the present disclosure may be utilized to ameliorate a problematic skin condition caused by various causes, or to safely and effectively alleviate or treat pruritus and/or atopy without concern about side effects.

Abstract: The present disclosure provides compositions and methods to prevent or reduce the encrustation of medical devices inserted in the urinary tract, such as a urinary stents (e.g., JJ stents). The reduction or prevention can result in an improvement in the quality of life of the patient by, e.g., reducing pain and/or tissue damage caused during the removal of an encrusted device.

Abstract: Disclosed are a fudosteine solution preparation for aerosol inhalation, and a preparation method therefor. The fudosteine solution preparation for aerosol inhalation comprises fudosteine, salts thereof and/or hydrates thereof; a metal complexing agent; and water for injection.

Abstract: A topical composition that includes L-arginine that is used as a sports health composition. The composition can further include forskolin. Disclosed is a method of using the topical composition.

Abstract: The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.

Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Abstract: There are provided various compositions comprising monoglyceride(s), diglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.

Abstract: A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or ?-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.

Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.

Abstract: Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer.

Abstract: This disclosure relates to inhibitors of Mcl-1 stimulated homologous recombination (HR) DNA repair and uses for treating cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an inhibitor of Mcl-1 in combination with other anti-cancer agents, e.g., that induce DNA replication stress. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering compounds disclosed herein in combination with hydroxyurea, olaparib, or combinations thereof.

Abstract: A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a method of manufacturing the powdered composition, a method of manufacturing the orally dispensable delivery vehicle, composition for use as a medicament, composition for use in a treatment, method of treatment, and use of a basic ion exchange resin as a stabilizing agent are disclosed.

Abstract: The invention relates to a unique formulation for brain health. The formulation includes a mixture of CBD and THC and/or flavonoids, along with at least one antioxidant, and preferably an emulsifier, spearmint extract and a film-forming agent. The formulation improves memory and cognition as well as prevents and improves symptoms in dementia and related diseases related to deterioration or loss of memory and/or cognition.

Abstract: A cannabinoid composition including a cannabinoid oil, such as THC oil or CBD oil, one or more thickeners such as gums, and a compound that forms an inclusion complex with the cannabinoid oil. The composition may include water, and in intermediate stages can include an alcohol. The composition can also include a sweetener to make it a sugar or a syrup. In some embodiments there are no other oils in the composition.

Abstract: The present disclosure generally relates to terpene-based compositions for applications in the pharmaceutical and recreational fields. In some embodiments, the compositions are enriched compositions or non-naturally occurring compositions which contain defined concentrations of one or more cannabis-derived chemical compounds, such as terpenes and cannabinoids that have a distinctive characteristic that mimics that of a cannabis plant matter or a product thereof. Also provided in some embodiments of the disclosure are methods for the preparation of the compositions, as well as methods for use thereof.

Abstract: The present invention provides cannabinoid and terpenoid compositions, among others, and methods of use including as medicines, supplements and nutraceuticals.

Abstract: The present invention provides a composition for preventing or mitigating dementia in a subject comprising a mixture of tocotrienols, tocopherol, squalene and B vitamin, and a pharmaceutically acceptable carrier.

Abstract: Antioxidative stress compositions, methods of using antioxidative stress composition and methods of preparing antioxidative stress composition compositions are described. The antioxidative stress compositions may be chemopreventive and/or immunomodulatory. Resveratrol, genistein, ellagic acid, curcumin and quercetin may be included in the antioxidative stress composition compositions individually or in any combination.

Abstract: The present invention provides a method for treating a protein aggregation disease, including: administering a pharmaceutical composition comprising a compound represented by the following formula (I) to a subject in need thereof, wherein each R1, R2, R3, R4, R5 and R6 are defined in the specification.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder and central nervous system diseases containing fluoxetine and vitamin C as active ingredients.

Abstract: The present disclosure relates to a novel dosing regimen for the administration of siponimod or pharmaceutically acceptable co-crystals or salts thereof, in the treatment of stroke, in particular ischemic stroke, e.g. acute ischemic stroke.

Abstract: The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.

Abstract: Described herein is a method for producing indole-3-propionic acid and other indole derivatives via bacterial fermentation and compositions of the same. The method comprises adding bacteria having a nucleic acid sequence with at least 80% homology to the nucleic acid sequence of SEQ ID NO: 1 to a liquid fermentation medium; fermenting at about 36° C. under anaerobic conditions; adding a dehydrating agent; and dehydrating to obtain a fermentate powder comprising indole-3-propionic acid and other indole derivatives.

Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.

Abstract: The present invention relates to pharmaceutical compositions of Eliglustat. In particular the present invention relates to stable amorphous Eliglustat premix having enhanced stability and dissolution properties. The present invention also provide a stable premix composition comprising amorphous Eliglustat or a pharmaceutical acceptable salt thereof, pharmaceutical compositions comprising the premixes, and processes for preparing the same. The compositions prepared in the present invention includes sublingual or mouth dissolving tablets, and capsules of Eliglustat and/or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier.

Abstract: The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: The present invention discloses a pharmaceutical tablet with a first layer comprising telmisartan, and a second layer comprising hydrochlorothiazide, amiodipine, mannitol, microcrystalline cellulose and corn starch, and a method of producing such a tablet.